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Summary Numerous tumor antigens have so far been identiﬁed from various tumors using the
serological identiﬁcation of antigens by recombinant expression cloning (SEREX) method. Among
them, cancer/testis (CT) antigens are considered promising target molecules for immunother-
apy for patients with various cancers. We performed several SEREX analyses of various cancers
to identify CT antigens, including gastric adenocarcinoma, lung adenocarcinoma, and colon
cancer, and consequently identiﬁed additional CT antigens, such as XAGE-1, CCDC62-2, GKAP1,
and TEKT5. However, although SEREX analysis of squamous cell carcinoma of the head and neck
(HNSCC) has been performed several times, only a few CT or HNSCC speciﬁc antigens have yet
been isolated. Compared with other tumors, a small number of studies have been reported on
the antigen proteins speciﬁc to HNSCC. We here reported the expression of selected CT anti-
gens and their immunogenicity in patients with HNSCC. The results obtained suggested thatT5 aCCDC62-2, GKAP1, and TEK
cies as diagnostic markers for pa
as NY-ESO-1, MAGE-A3, and MAG
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. Introduction
he incidence of squamous cell carcinoma of the head
nd neck (HNSCC) is more than 20,000 new cases per year
n Japan and ∼500,000 cases annually worldwide. Surgi-
al resection is commonly performed followed by combined
hemotherapy or radiotherapy. However, the 5-year sur-
ival rates of patients with this cancer have remained
t approximately 50% for the past 2 decades, in spite of
dvances in surgical procedures as well as various combi-
ations of chemotherapeutic agents [1,2]. Therefore, the
evelopment of new therapeutics and their integration into
urrent forms of therapy remain a major goal for the
uture. Recent progresses in tumor immunology based on
he molecular identiﬁcation of tumor antigens may allow
mmunotherapy to become another promising treatment to
mprove the outcomes of patients with HNSCC. Following
he introduction of the T cell epitope cloning technique by
oon et al. [3], numerous antigens coding for immunogenic
equences have been identiﬁed in different tumor types,
ncluding MAGE families in malignant melanoma [4] and NY-
SO-1 in esophageal cancer [5]. Cancer/testis (CT) antigens
ave become promising targets for the diagnosis of and
mmunotherapy for patients with various tumors because of
heir unique expression patterns [6]. Compared with other
umors, a small number of studies have been reported on the
ntigen proteins speciﬁc to HNSCC [7,8]. We here reported
he expression of selected CT antigens and their immuno-
enicity in patients with HNSCC.
. CT antigens
he deﬁning characteristics of CT antigens are high levels
f expression in male germ cells such as spermatogonial
tem cells, spermatogonia, spermatocytes, spermatids, and
Table 1 List of known CT antigens and CT antigen families.
CT antigen No. of genes Chromosome
MAGE-A 11 Xq28
BAGE 5 13
GAGE 8 Xp11.4-11.2
SSX 9 Xp11.2
NY-ESO-1/LAGE-1 2 Xq28
SCP1 1 1p13
CT7/MAGE-C1 1 Xq26-27
CT8/HOM-TES-85 1 Xq24
CT10 1 Xq27
cTAGE 5 18p11
XAGE-1 5 Xp11.21-22
OY-TES-1 1 12p13.31
AKAP3 1 12p13.3
CCDC62-2 1 12q24.31
GKAP1 1 9q21.32
TEKT5 1 16p13.13
aberrantly expressed in a wide range of different tumor
types and have been shown to be antigenic in tumor-bearing
patients [12]. CT antigens are now classiﬁed as X-CT and
non-X-CT based on whether the gene is located on the X
chromosome (Table 1). X-CT antigens are often organized
in well-deﬁned clusters to constitute multigene families
[13,14]. However, genes encoding non-X-CT antigens are dis-
tributed throughout the genome and are mostly single-copy
genes. Since different CT antigens are expressed during dif-
ferent stages of spermatogenesis (Fig. 1), their function may
be versatile, e.g. the regulation of mitotic cycling in sper-
matogonia, an association with the meiotic cycle in sperma-
tocytes, and ﬁnalizing acrosome maturation in sperm.
More than 110 genes or gene families coding for CT
permatozoa during spermatogenesis in the testis, and lack
f expression in normal tissues [9]. The expression of CT
ntigens has also been reported in the ovary and pla-
enta [10,11]. The genes of CT antigens are activated and
a
o
i
(ntigens have been identiﬁed to date by several method-
logies [15], such as T-cell epitope cloning, serological
dentiﬁcation of antigens by recombinant expression cloning
SEREX), representational difference analysis (RDA), DNA
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CCDC62-2, and OY-TES-1 are shown. MAGE-A and CCDC62-2 prot
microarray analysis, and bioinformatics. The T-cell epitope
cloning method developed by Boon et al. in 1991 resulted
in the discovery of MAGE-A1, BAGE, and GAGE1 [3,16,17],
and RDA led to the cloning of LAGE-1, MAGE-E1, and SAGE
[18—20]. MAA-1A was identiﬁed using DNA microarray
analysis [21]. More recently, bioinformatics-based analysis
resulted in the cloning of BRDT, OY-TES-1, PAGE5, LDHC,
and TPTE [22—25]. Of these methods, SEREX appears to
be effective for the identiﬁcation of CT antigens. SSX2,
SYCP-1, and NY-ESO-1 were isolated using cDNA libraries
from cancer or normal testis tissues [26—28]. Additional CT
antigens, such as XAGE-1, CCDC62-2, GKAP1, and TEKT5,
were identiﬁed in our SEREX analysis [29—32].
3. SEREX
SEREX was developed in 1995 by Pfroundschuh et al. to
combine serological analysis with antigen cloning tech-
niques in order to identify human tumor antigens eliciting
high-titer immunoglobulin G (IgG) antibodies [33]. The
SEREX technique is shown schematically in Fig. 2. In
brief, serum samples, which had been diluted 1:10,
were preabsorbed with lysate from Escherichia coli and
w
r
t
lgenesis. The unique expression patterns of MAGE-A, NY-ESO-1,
xpression is also shown in human adult testis tissues.
acteriophage-infected E. coli coupled to sepharose 4B.
itrocellulose membranes containing the phage plaques at a
ensity of approximately 4000 pfu/140mm plate were incu-
ated overnight at room temperature with the preabsorbed
utologous serum, which had been diluted 1:200. Reacted
lones were detected using peroxidase-conjugated goat
nti-human IgG and visualized with 3-3′-diaminobenzidine.
ositively-reacted clones were subcloned to monoclonality,
uriﬁed, and excised in vivo to pBK-CMV plasmid forms. Plas-
id DNA was prepared and the nucleotide sequence of cDNA
nserts was determined by a DNA sequencer.
SEREX utilizes the sera of cancer patients, which con-
ain antibodies against a various tumor antigens, to screen
or tumor antigens in cDNA expression libraries constructed
rom tumor tissues or cell lines. In the initial set of
xperiments, Sahin et al. analyzed melanoma, renal cell
arcinoma, astrocytoma and Hodgkin lymphoma, which
esulted in the isolation of a large number of genes [34].
hese included MAGE-A1 and tyrosinase, two antigens pre-
iously shown to be targets for cytotoxic T lymphocytes,
hich indicated that protein antigens that elicit antibody
esponses in cancer patients are likely to have elicited simul-
aneous T cell responses [33]. This ﬁnding prompted the
arge scale SEREX screening of various tumor types, and led
94 S. Domae et al.
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tFigure 2 Schematic repre
o the identiﬁcation of more than 1000 SEREX-deﬁned anti-
ens. It included several CT antigens such as MAGE-A, SSX,
Y-ESO-1, SCP1, and CAGE-1. We more recently identiﬁed
dditional CT antigens, such as XAGE-1, CCDC62-2, GKAP1,
nd TEKT5 using this method. SEREX has been performed
o screen HNSCC, and several HNSCC-speciﬁc antigens have
een isolated [35,36]. A screening of a testicular cDNA
xpression library with HNSCC patient sera has led to the
dentiﬁcation of a CT antigen, KM-HN-1 [37].
. CT genes and families
.1. MAGE
oon and colleagues reported the ﬁrst successful cloning of
human tumor antigen in 1991 using the melanoma cell
ine MZ2-MEL and autologous CTL clones, termed MAGE-1
subsequently re-named as MAGE-A1). It elicited a spon-
aneous CTL response in an autologous melanoma patient
3]. Boon et al. identiﬁed MAGE-A3, another member of the
AGE-A family, using the same strategy. Since then, the
AGE family has expanded to include over 60 genes [38].
n mRNA expression analysis revealed that MAGE-A genes
ere expressed in the testis, but not in other normal adult
issues. These genes have also been shown to be expressed
n various cancers, including HNSCC. MAGE-A3 is frequently
xpressed in melanoma, non-small-cell lung cancer, bladder
ancer, and liver cancer [39—41]. Its tumor speciﬁcity makes
t a potentially safe and valuable target for immunotherapy.
s
t
c
otion of the SEREX method.
everal clinical trials have tested peptide-based vaccines
nd recombinant protein vaccines in melanoma patients and
ung cancer patients [42—44].
.2. NY-ESO-1
Y-ESO-1 was originally identiﬁed in esophageal cancer by
hen et al., who performed SEREX on autologous patient
erum [5]. NY-ESO-1 belongs to a family of at least two
enes, NY-ESO-1 and LAGE-1, mapped in tandem on chro-
osome Xq28. NY-ESO-1 has been the focus of increasing
ttention because of its strong immunogenicity and has
merged as a prototype of CT antigens. A spontaneous
Y-ESO-1-speciﬁc antibody response has frequently been
bserved in patients with various types of advanced stage
umors expressing NY-ESO-1 [45,46]. Clinical trials using the
Y-ESO-1 peptide, protein, and viral constructs as cancer
accines have successfully reported the efﬁcient induction
f antibodies, and CD4 and CD8 T cell responses [47—49].
.3. SSX
EREX screening of a testicular cDNA expression library
ith sera from melanoma patients led to the identiﬁca-
ion of HOM-MEL-40 [33], a gene identical to the synovial
arcoma/X breakpoint 2 gene (SSX-2) involved in t (x: 18)
ranslocation in synovial sarcoma [50]. The SSX family is
omposed of at least 9 SSX genes, all of which are located
n chromosome Xp11.2. SSX2 and 4 genes are frequently
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expressed in tumor tissues. SSX proteins were shown to be
localized to the nuclei of spermatogonia and early sperma-
tocytes in the human testis. Anti-SSX1, 2, 3, and 4 antibodies
have been detected in patients with various types of tumors,
including melanoma, colon, breast, and ovarian cancers
[51,52]. However, clinical trials using SSX proteins as vac-
cines have been unsuccessful.
4.4. OY-TES-1
OY-TES-1 was shown to be a member of CT antigen family
by Ono et al. [23]. This gene is located on chromo-
some 12p13.31 and encodes the human homologue of the
proacrosin binding protein sp32 precursor, which was ini-
tially detected in other mammal species, such as the pig
and mouse. sp32 is located in the sperm acrosome and
appears to function as a binding protein to proacrosin
for the packaging and condensation of acrosin zymogen in
the acrosomal matrix. OY-TES-1 is known to be expressed
in a range of different tumor types, including bladder,
breast, lung, liver, colon, prostate, and ovarian cancers.
A serological survey of 362 patients with a range of dif-
ferent cancers revealed an antibody to OY-TES-1 in 25
patients. The anti-OY-TES-1 antibody was detected in ∼10%
of ovarian cancer patients whose tumors expressed the
antigen. A previous study reported that high expression lev-
els of OY-TES-1 in ovarian cancers correlated with survival
times and faster relapses among ovarian cancer patients
[53]. These ﬁndings indicated that OY-TES-1 could be a
target for immunotherapy [54]. The down-regulation of
OY-TES-1 expression in mesenchymal stem cells was more
recently shown to cause cell cycle arrest and a decrease
in migration, which indicated that OY-TES-1 may inﬂu-
ence the biological behavior of mesenchymal stem cells
[55].
4.5. AKAP3
A-kinase anchoring proteins (AKAPs) are a group of struc-
turally diverse proteins that bind to the regulatory subunit
of PKA, and are signaling scaffolds that contribute to various
aspects of cAMP signaling [56]. AKAP-mediated PKA acti-
vation was previously shown to inhibit cell growth in the
muscle and T lymphocytes [57,58]. AKAP3 is a testis-speciﬁc
protein that is exclusively expressed in round spermatids.
We previously demonstrated that AKAP3 was a CT antigen,
and also that the expression of AKAP3 mRNA was marked
in ovarian cancer and correlated with the histological grade
and clinical stage of the tumor. We also found that AKAP3
mRNA expression was an independent and favorable pro-
gnostic factor in patients with poorly differentiated ovarian
cancer [59].
4.6. XAGE-1
XAGE-1 was originally identiﬁed by EST database mining and
found to be highly expressed in normal testis and Ewing’s
sarcoma [60]. The XAGE-1 gene is located on chromosome
Xp11.21-22, consists of 4 exons, and shows homology to
GAGE/PAGE genes. Four transcript variants, XAGE-1a, b, c
t
b
[
F95
nd d, have been identiﬁed to date. Of these, XAGE-1b was
hown to be the major transcript [61]. Using SEREX anal-
sis, Ali Eldib et al. identiﬁed XAGE-1b as the dominant
ntigen recognized by serum from a lung adenocarcinoma
atient from an autologous tumor cell line established from
alignant pleural effusion as a cDNA library source [29].
pproximately 10% of lung adenocarcinoma patients showed
ntibody responses. CD4 and CD8 T cell responses against
AGE-1b were also elicited in antibody-positive lung adeno-
arcinoma patients, which demonstrated that XAGE-1b is a
romising antigen for immunotherapy against lung adeno-
arcinoma [62].
.7. CCDC62-2
EREX analysis identiﬁed coiled-coil domain containing 62
CCDC62) in a testicular cDNA library and serum obtained
rom a gastric adenocarcinoma patient in whom primary
ancer had regressed once and most liver metastases had
ransiently disappeared. The CCDC62 gene consists of 13
xons and is located on chromosome 12q24.31. It has
splice variants of 2481 bp (CCDC62-1, NM 032573) and
044 bp (CCDC62-2, NM 201435), which encode proteins
f 682 amino acids and 684 amino acids, respectively.
T-PCR analysis revealed that the expression of both vari-
nts was restricted to the testis in normal adult tissues.
he expression of CCDC62-1 mRNA was absent, whereas
hat of CCDC62-2 mRNA was observed in several types of
umors. In a large scale ELISA survey of 191 serum sam-
les collected from patients with several types of cancer,
3 patients were found to have produced an antibody to the
CDC62-2 protein, including stomach cancer. Western Blot
nalysis revealed reactions against recombinant CCDC62-2
olecules. CCDC62-2 was identiﬁed as a novel CT antigen
hat is immunogenic in cancer patients [30].
.8. GKAP1
-kinase anchoring protein 1 (GKAP1) was also identiﬁed
y SEREX analysis using a testicular cDNA library and serum
btained from a gastric adenocarcinoma patient. It was iso-
ated by a yeast two-hybrid system using a mouse embryo
ibrary and reported as the male germ cell-speciﬁc 42-kDa
rotein, GKAP42 [63]. We successfully cloned human GKAP1
DNA and demonstrated that the expression of GKAP1 mRNA
as the highest in the testis of normal adult tissues and
n various cancers [30,31]. GKAP1 functions as an anchor-
ng protein for cGK-I and appears to be similar to AKAP (A
inase anchoring protein), which binds to cAK via its regu-
atory subunits.
.9. TEKT5
anafusa et al. performed SEREX analysis on colon cancer,
nd identiﬁed the novel CT antigen, Tektin 5 (TEKT5) [32].
ETKs are composed of a family of ﬁlament-forming pro-
eins in the male germ cell-lineage in centrioles and basal
odies and within ciliary and ﬂagellar doublet microtubules
64]. They were originally isolated from sea urchin sperm.
ive types of mammalian Tektins have been identiﬁed in
96 S. Domae et al.
Figure 3 Protein expression of CT antigens in a HNSCC tissue sample. A HLA class I positive HNSCC specimen was immunohis-
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mAb C8/144b).
arious animals, including the mouse, rat, and human [65].
EKT5 was initially identiﬁed in the rat. It is present in sperm
agella, plays an important role in ﬂagella formation dur-
ng spermiogenesis, and has also been implicated in sperm
otility. The human TEKT5 gene consists of 7 exons and is
ocated on chromosome 16p13.13. The expression of TEKT5
RNA was restricted to the testis in normal adult tissues. It
as detected in several types of cancers, including colon,
astric, liver, lung, and prostate cancers, but not in HNSCC.
DNA microarray analysis revealed that the expression of
EKT5 was higher in 2 of 3 colon cancer tissues than in nor-
al tissue. It was also up-regulated by more than 3-fold in
0% of the lung cancer specimens examined. Thus, TEKT5
as a classical future as a CT antigen. In our survey of 101
ancer patients with several types of cancer, 13 patients
ere found to have produced an antibody to the TEKT5 pro-
ein. No reactivity was observed in sera from healthy donors.
ETK5 appears to have high immunogenic potential in terms
f antibody frequency [32].
p
b
C), XAGE-1b (mAb USO 9-13), CCDC62-2 (mAb 6212-1), and CD8
. Expression and humoral response of CT
ntigens to HNSCC
e evaluated the patterns and levels of expression of 8 CT
enes by RT-PCR from a panel of primary HNSCC. Over 50%
f the tumors examined expressed at least 1 CT gene. The
oexpression of two or more genes was detected in 23% of
NSCC. The most frequently expressed gene was MAGE-A4
32%), followed by MAGE-A3 (24%), GKAP1 (18%), MAGE-A1
13%), CCDC62-2 (12%), SSX-2 (11%), XAGE-1b (7%), and NY-
SO-1 (3%) [31]. Using monoclonal antibodies, the expression
f CT antigen proteins in multigene-expressed HNSCC tissue
as analyzed using an immunohistochemical technique. The
eterogeneous expression of CCDC62-2 and MAGE-A proteins
as detected in HLA class I positive HNSCC (Fig. 3). CD8
ositive T cells were also occasionally observed.
Humoral immune responses in cancer patients have
een investigated broadly by ELISA against recombinant
T antigen proteins. The frequency of antibody responses
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to MAGE was shown to be low in these patients [7,45]. In
contrast, the anti-NY-ESO-1 antibody has been detected
in many cancer types, including melanoma, lung, ovarian,
breast, and bladder cancer. Approximately 7% of bladder
cancer patients and 4% of esophageal cancer patients in
Japan showed NY-ESO-1 antibody responses [66,67]. The
frequency of anti-NY-ESO-1 antibody responses in patients
with advanced NY-ESO-1 positive tumors has been estimated
to be in the range of 25—50%, and the titer of the antibody
appears to increase with progressive disease and decrease
upon removal of the tumor or tumor regression [68]. The
occurrence of CD4 and CD8 T-cell responses in NY-ESO-1
antibody-positive patients demonstrated the strong cellular
immunogenicity of the NY-ESO-1 antigen. An integrated
immune response including the antibody and CD4 and CD8
T-cell responses was repeatedly shown in patients with
NY-ESO-1-expressing tumors [46,47,69]. As potential cancer
vaccine targets, the conﬁrmation of immunogenicity in the
human host is considered crucial for CT antigens. Only a few
CT antigens have so far been shown to elicit coordinated
humoral- and cell-mediated responses. T-cell responses to
CT antigens are typically examined by screening overlapping
peptide panels with CD8 or CD4 T-cells from human periph-
eral blood mononuclear cell (PBMC). Many HLA-restricted
T-cell epitopes have been identiﬁed this way, particularly
for MAGE-A, NY-ESO-1, and SSX genes, and has formed
the basis for peptide-based CT cancer vaccine trials and
the monitoring of post-vaccination T-cell responses
(http://www.cancerimmunity.org/peptidedatabase/
Tcellepitopes.htm).
Therefore, the immunogenicity of 2 novel CT antigens,
CCDC62-2 and GKAP1, against HNSCC patients was analyzed
by examining serum reactivity with ELISA using recombi-
nant proteins. A total of 3/18 and 2/18 serum samples from
HSNCC patients were reactive against CCDC62-2 and GKAP1,
respectively (Fig. 4). None of the healthy donor serum was
reactive. Three serum samples from the same panel of sera
were also reactive against TEKT5 [32]. Taken together, these
ﬁndings suggest that the serologically-deﬁned CT antigens,
CCDC62-2, GKAP1, and TEKT5, may provide a molecu-
lar basis for diagnostic and immunotherapeutic targets in
HNSCC patients.
W
a
h
sainst CCDC62-2 and GKAP1 proteins by ELISA.
. Conclusion
mmunotherapy includes both non-speciﬁc immunomodula-
ion as well as cell-mediated immunotherapy and related
reatment strategies that have the development of antigen-
peciﬁc CD4 and CD8 T cell responses as their goal. Various
mmunotherapeutic approaches have been assessed clini-
ally, but have had limited success, especially in HNSCC.
ver the last decade, the importance of regulatory T cells
nd other mechanisms that limit a wide variety of physiolog-
cal and pathological immune responses to tumor antigens
nd peptides has become clear. New strategies are cur-
ently being developed to overcome these obstacles in order
o develop effective cell-mediated immunotherapy. Recent
rogresses in tumor immunology based on the molecular
dentiﬁcation of tumor antigens may allow immunotherapy
o become another promising treatment to improve the out-
omes of cancer patients. Following the introduction of the
cell epitope cloning technique by Boon et al., numerous
ntigens coding for immunogenic sequences have been iden-
iﬁed in different tumor types, including MAGE families in
alignant melanoma and NY-ESO-1 in esophageal cancer.
ancer/testis (CT) antigens have become promising targets
or the diagnosis of and immunotherapy for patients with
arious tumors because of their unique expression patterns.
erologically-deﬁned novel CT antigens such as CCDC62-2,
KAP1, and TEKT5 were shown to be immunogenic in HNSCC
atients, and this ﬁnding may provide provided a molecu-
ar basis for diagnostic and immunotherapeutic targets in
NSCC patients.
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